Posted by Michael Wonder on 26 May 2022
Reata Pharmaceuticals announces FDA filing acceptance and priority review designation for the NDA for omaveloxolone for the treatment of patients with Friedreich’s ataxia
26 May 2022 - Application assigned a PDUFA date of 30 November 2022.
Reata Pharmaceuticals today announced that the U.S. FDA has accepted for filing and granted priority review of its new drug application for omaveloxolone for the treatment of patients with Friedreich’s ataxia.
